Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

1.

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Han F, Wu J, Huang H, Zhang X, He Q, Wang Y, Wang S, Wang H, Chen J.

Exp Clin Transplant. 2011 Feb;9(1):42-9.

PMID:
21605022
[PubMed - indexed for MEDLINE]
Free Article
2.

Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.

Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.

Clin J Am Soc Nephrol. 2012 Mar;7(3):504-12. doi: 10.2215/CJN.06940711. Epub 2012 Jan 26.

PMID:
22282478
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.

Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M.

J Nephrol. 2011 Sep-Oct;24(5):613-8. doi: 10.5301/JN.2011.6247.

PMID:
21240873
[PubMed - indexed for MEDLINE]
4.

Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.

Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.

Int J Artif Organs. 2009 Jun;32(6):371-80.

PMID:
19670189
[PubMed - indexed for MEDLINE]
5.

Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.

Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G.

J Nephrol. 2012 Sep-Oct;25(5):709-18. doi: 10.5301/jn.5000044.

PMID:
22038336
[PubMed - indexed for MEDLINE]
Free Article
6.

Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.

Knight RJ, Podder H, Kerman RH, Lawless A, Katz SM, Van Buren CT, Gaber AO, Kahan BD.

Transplantation. 2010 Mar 27;89(6):727-32. doi: 10.1097/TP.0b013e3181c9dc9b.

PMID:
20195219
[PubMed - indexed for MEDLINE]
7.

Conversion to sirolimus in kidney transplant recipients: a single-center study.

Ganji MR, Hakemi MS, Esfehani F, Alatab S, Naderi GH.

Iran J Kidney Dis. 2013 Jul;7(4):309-15.

PMID:
23880809
[PubMed - indexed for MEDLINE]
Free Article
8.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
[PubMed - indexed for MEDLINE]
9.

Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.

Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.

Transplantation. 2009 Aug 15;88(3):421-8. doi: 10.1097/TP.0b013e3181af1df6.

PMID:
19667948
[PubMed - indexed for MEDLINE]
10.

High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.

Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J.

Transplant Proc. 2012 Dec;44(10):2961-5. doi: 10.1016/j.transproceed.2012.07.142.

PMID:
23195006
[PubMed - indexed for MEDLINE]
11.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
[PubMed - indexed for MEDLINE]
Free Article
12.

Reduced exposure to calcineurin inhibitors in renal transplantation.

Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study.

N Engl J Med. 2007 Dec 20;357(25):2562-75.

PMID:
18094377
[PubMed - indexed for MEDLINE]
Free Article
13.

Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.

Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.

Transplant Proc. 2011 Jul-Aug;43(6):2187-90. doi: 10.1016/j.transproceed.2011.06.055.

PMID:
21839229
[PubMed - indexed for MEDLINE]
14.

Can we eliminate both calcineurin inhibitors and steroids?

Lebranchu Y.

Transplant Proc. 2010 Nov;42(9 Suppl):S25-8. doi: 10.1016/j.transproceed.2010.07.002. Review.

PMID:
21095446
[PubMed - indexed for MEDLINE]
15.

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.

Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group.

Transplantation. 2002 Dec 15;74(11):1560-7.

PMID:
12490789
[PubMed - indexed for MEDLINE]
16.

A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.

Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.

Transplant Proc. 2013 Jul-Aug;45(6):2387-92. doi: 10.1016/j.transproceed.2013.03.032.

PMID:
23953553
[PubMed - indexed for MEDLINE]
17.

Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.

Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.

Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.

PMID:
18773960
[PubMed - indexed for MEDLINE]
18.

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P.

Transplantation. 2000 Apr 15;69(7):1252-60.

PMID:
10798738
[PubMed - indexed for MEDLINE]
19.

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.

Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.

Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.

PMID:
19938140
[PubMed - indexed for MEDLINE]
Free Article
20.

Sirolimus in renal transplantation: analysis of safety and efficacy in a nonprotocol conversion group.

Gois PH, Rivelli GG, Pereira LM, Mazzali M.

Transplant Proc. 2012 Oct;44(8):2348-51. doi: 10.1016/j.transproceed.2012.07.010.

PMID:
23026590
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk